NCT04026321 - Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

December 6, 2018

Study Completion Date

December 11, 2018

Conditions

Solid Tumor Refractory to Standard Therapy

Interventions

DRUG

SQ001 125mL/day

SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute

DRUG

SQ001 250mL/day

SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute

DRUG

SQ001 500mL/day

SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute

DRUG

SQ001 625mL/day

SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute

DRUG

Saline 0.9%

Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute

Trial Locations (1)

Clinical Pharmacology of Miami, Inc., Miami